Modeling therapy resistance via the EGFR signaling pathway

Mutations in KRAS are often associated with resistance to EGFR‐targeting antibody therapy. Using comprehensive systems analyses, GNB5 has been identified as a potential target to overcome therapy resistance targeting the EGFR signaling pathways, whereby the AKT signaling pathway (PI3K) rather than t...

Descripción completa

Detalles Bibliográficos
Autores principales: Plattner, Christina, Hackl, Hubert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850018/
https://www.ncbi.nlm.nih.gov/pubmed/30892828
http://dx.doi.org/10.1111/febs.14809
_version_ 1783469325877772288
author Plattner, Christina
Hackl, Hubert
author_facet Plattner, Christina
Hackl, Hubert
author_sort Plattner, Christina
collection PubMed
description Mutations in KRAS are often associated with resistance to EGFR‐targeting antibody therapy. Using comprehensive systems analyses, GNB5 has been identified as a potential target to overcome therapy resistance targeting the EGFR signaling pathways, whereby the AKT signaling pathway (PI3K) rather than the ERK signaling pathway (RAS) might be dominantly affected. Personalized mathematical modeling and simulations of this signaling pathway/network and respective perturbations are of great utility to customize therapy for patients. [Image: see text]
format Online
Article
Text
id pubmed-6850018
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68500182019-11-15 Modeling therapy resistance via the EGFR signaling pathway Plattner, Christina Hackl, Hubert FEBS J Commentary Mutations in KRAS are often associated with resistance to EGFR‐targeting antibody therapy. Using comprehensive systems analyses, GNB5 has been identified as a potential target to overcome therapy resistance targeting the EGFR signaling pathways, whereby the AKT signaling pathway (PI3K) rather than the ERK signaling pathway (RAS) might be dominantly affected. Personalized mathematical modeling and simulations of this signaling pathway/network and respective perturbations are of great utility to customize therapy for patients. [Image: see text] John Wiley and Sons Inc. 2019-03-20 2019-04 /pmc/articles/PMC6850018/ /pubmed/30892828 http://dx.doi.org/10.1111/febs.14809 Text en © 2019 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Plattner, Christina
Hackl, Hubert
Modeling therapy resistance via the EGFR signaling pathway
title Modeling therapy resistance via the EGFR signaling pathway
title_full Modeling therapy resistance via the EGFR signaling pathway
title_fullStr Modeling therapy resistance via the EGFR signaling pathway
title_full_unstemmed Modeling therapy resistance via the EGFR signaling pathway
title_short Modeling therapy resistance via the EGFR signaling pathway
title_sort modeling therapy resistance via the egfr signaling pathway
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850018/
https://www.ncbi.nlm.nih.gov/pubmed/30892828
http://dx.doi.org/10.1111/febs.14809
work_keys_str_mv AT plattnerchristina modelingtherapyresistanceviatheegfrsignalingpathway
AT hacklhubert modelingtherapyresistanceviatheegfrsignalingpathway

Ejemplares similares